TL49: Risk Stratification Strategies to Identify Low-Risk Patients In Cardiovascular Clinical Trials
*CV Damaraju, Janssen Research and Development, LLC  *Juliana Ianus, Janssen R&D 

Keywords: risk stratification, anticoagulants, VTE, outpatients

With rising costs of health care utilization including hospitalizations, it has become imperative to identify low-risk patients suitable for treatment on an outpatient basis. This is particularly true when treating patients with anticoagulants to prevent potential blood clots. Though not uncommon, the bleeding complications during anticoagulant treatment require an efficient method to screen and estimate the bleeding risk for an individual patient before the start of anticoagulant treatment itself. Several risk scores have been developed to estimate the overall cardiovascular disease risk of an individual. Cardiovascular risk scoring systems also indicate who is most likely to benefit from prevention. For this reason, cardiovascular risk scores can be used to select the patients at low risk from complications to facilitate their treatment as outpatients with specific anticoagulants. We plan to discuss several validated risk scoring strategies that aim to predict the bleeding risk of the patients who begin to use anticoagulant treatments for preventing Venous Thromboembolism (VTE) events.